Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose in the January 15, 2025, Information Statement and subsequent amendment issued by Defen ...

New York, New York--(Newsfile Corp. - January 27, 2026) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Wealthfront Corporation (NASDAQ: WLTH) for potential violations of the federal securities laws. If you invested in Wealthfront, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/wealthfront-corporation-class-action.Why is Wealthfront Being Investigated for Violations of the Federal Securities Laws? Wealthfront is an onli ...

Core Viewpoint - Alexandria Real Estate Equities, Inc. is facing a federal securities class action due to allegations of making false and misleading statements regarding its Long Island City property and overall financial performance [1][3]. Financial Performance - Alexandria reported third quarter earnings for 2025 that fell short of analyst expectations, with a 5% decline in revenue and a 7% decline in adjusted funds from operation [4]. - The average occupancy rate decreased from 94.8% in the previous year to 91.4% [4]. - Following the financial results announcement, Alexandria's stock price dropped over 19% on October 28, 2025 [4]. Legal Proceedings - The law firm Faruqil & Faruqil, LLP is investigating potential claims against Alexandria and has set a deadline of January 26, 2026, for investors to seek the role of lead plaintiff in the class action [1][5]. - The complaint alleges that the company and its executives provided overwhelmingly positive statements while concealing material adverse facts about the company's property [3].

Core Viewpoint - Ultragenyx Pharmaceutical Inc. is under investigation for potential violations of federal securities laws following the failure of its Phase III studies to meet primary endpoints related to fracture rate reduction [1][2]. Group 1: Study Results - The Phase III studies, Orbit and Cosmic, did not achieve their primary endpoint of reducing annualized clinical fracture rates compared to placebo and standard care, respectively [2][3]. - Despite showing improvements in bone density, the studies failed to correlate these results with a reduction in fracture rates [3]. Group 2: Company Response and Analyst Reactions - In response to the study results, Ultragenyx management cited a "low fracture rate in the placebo group" as a reason for the failed outcomes, claiming no "uncontrolled factors" were present in the study design [4]. - Following the announcement, analysts became cautious, with Barclays indicating limited opportunity for drug approval despite some clinical benefits observed [4].

Core Insights - The complaint alleges that BellRing and its executives violated federal securities laws by making false or misleading statements regarding the sustainability and drivers of sales growth, as well as the impact of competition on product demand [2] Group 1: Sales Performance and Market Reaction - On May 5, 2025, BellRing disclosed that several key retailers reduced their weeks of supply, which would negatively impact Q3 2025 growth. The stock price fell by $14.88, or 19%, from $78.43 to $63.55 on May 6, 2025, with unusually high trading volume [3] - On August 4, 2025, BellRing reported disappointing quarterly consumption of Premier Protein RTD Shakes, which aligned more closely with shipments than expected. This led to a stock price drop of $17.46, or nearly 33%, from $53.64 to $36.18 on August 5, 2025 [4] Group 2: Legal Proceedings - The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class, who will oversee the litigation on behalf of the class members. Class members can choose to serve as lead plaintiff or remain absent without affecting their ability to share in any recovery [5] - Faruqi & Faruqi encourages individuals with information regarding BellRing's conduct to come forward, including whistleblowers and former employees [6]

Core Viewpoint - Wealthfront Corporation is under investigation for potential violations of federal securities laws, particularly concerning misleading statements made during its IPO process [1][3]. Group 1: Company Overview - Wealthfront is an online financial advisor that utilizes automated tools to provide investment and financial advice [2]. - The company completed its initial public offering (IPO) on December 12, 2025, offering over 34 million shares at a price of $14.00 per share [2]. Group 2: Investigation Details - The investigation by Bleichmar Fonti & Auld LLP focuses on whether Wealthfront made false and misleading statements to investors, especially in the IPO offering materials [3]. Group 3: Stock Performance and Financial Results - On January 12, 2026, Wealthfront reported its first quarterly results as a public company, revealing net deposit outflows of $208 million, a significant decline from the $874 million inflows during the same period the previous year [4]. - Following the earnings report, Wealthfront's stock price dropped by $2.12 per share, nearly 17%, from $12.59 to $10.47 on January 13, 2026 [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Wealthfront Corporation for possible violations of federal securities laws and unlawful business practices affecting stockholders [1][2]. Investigation Details - The investigation focuses on whether Wealthfront has engaged in practices that may have harmed investors, particularly in light of recent financial disclosures [2]. Financial Performance - Wealthfront reported significant net deposit outflows of $208 million for Q3 2026, a stark contrast to $874 million in inflows during the same period the previous year [6]. - The CEO, David Fortunato, attributed the decline in deposits to a decrease in interest rates and highlighted the importance of the newly launched home-lending business to counteract this trend [6]. - Following the financial results announcement, Wealthfront's stock price dropped by $2.12, or 16.8%, closing at $10.47 per share on January 13, 2026, resulting in losses for investors [6].

Core Viewpoint - Vistagen Therapeutics, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its Phase 3 PALISADE-3 trial of fasedienol, which did not meet its primary endpoint, leading to a significant drop in stock price [3][4]. Group 1: Company Overview - Vistagen Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for social anxiety disorder [3]. - The company’s investigational drug, fasedienol, was under evaluation in the Phase 3 PALISADE-3 trial [3]. Group 2: Trial Results and Allegations - The PALISADE-3 trial did not show a statistically significant improvement on the primary endpoint, which was the change on the Subjective Units of Distress Scale [3]. - Defendants allegedly provided positive statements while concealing adverse facts about the trial results [3]. Group 3: Stock Price Impact - Following the announcement of the trial results on December 17, 2025, Vistagen's stock price plummeted from $4.36 per share to $0.86 per share, representing a decline of over 80% [3]. Group 4: Legal Proceedings - Shareholders who purchased shares during the class period from April 1, 2024, to December 16, 2025, are encouraged to register for the class action lawsuit [4]. - The deadline for shareholders to seek lead plaintiff status is March 16, 2026 [4].

Core Viewpoint - PDD Holdings is under investigation for potential securities law violations following increased regulatory scrutiny from Chinese authorities, which has disrupted the company's operations [2][4]. Group 1: Regulatory Scrutiny - Shares of PDD Holdings experienced a decline on January 20, 2026, due to reports of expanded regulatory scrutiny by Chinese authorities after a confrontation between PDD personnel and government inspectors [2]. - Multiple regulatory agencies, including China's market and tax authorities, have conducted large-scale inspections at PDD's Shanghai offices, focusing on delivery practices and tax compliance [2]. Group 2: Legal Investigation - Block & Leviton is investigating whether PDD Holdings committed securities law violations and may pursue legal action to recover losses for affected investors [4]. - Investors who have lost money on their PDD Holdings investment are encouraged to contact Block & Leviton for potential recovery options [3][5]. Group 3: Whistleblower Information - Individuals with non-public information about PDD Holdings are encouraged to assist in the investigation or report to the Securities Exchange Commission under the whistleblower program, which offers rewards of up to 30% of any successful recovery [6]. Group 4: Firm's Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

Core Insights - Apogee Enterprises, Inc. is under investigation for potential violations of federal securities laws following the release of its fiscal third quarter 2026 financial results, which indicated a decline in profitability expectations [1][2]. Financial Performance - Apogee reported a decrease in gross margin to 23.8% from 26.1% and a slight decline in adjusted EBITDA margin to 13.2% from 13.4% for the third quarter of fiscal 2026 compared to the same period in fiscal 2025, indicating reduced future profitability [2]. - The company has revised its fiscal 2026 outlook, lowering net sales expectations from $1.44 billion to $1.39 billion and adjusted EPS from a range of $3.80 - $4.20 to $3.40 - $3.50 [2]. Market Reaction - Following the announcement of the financial results and the investigation, Apogee's stock price fell by $6.29, or 17%, opening at $31.00 per share [3].